Current strategies in previously untreated advanced colorectal cancer

ONCOLOGY

Volumn 18, Issue 6, 2004, Pages 715-727

  Penland, Shannon K ^a   Goldberg, Richard M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PLATINUM COMPLEX;

COLORECTAL TUMOR; HUMAN; LIVER TUMOR; METASTASIS; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 33144482991     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. American Cancer Society: Cancer Facts and Figures 2003. Atlanta, American Cancer Society, 2003.
2. August DA, Ottow RT, Sugarbaker PH: Clinical perspective of human colorectal cancer metastases. Cancer Metastases Rev 3:303, 1984.
3. Sobrero AF, Aschele C, Bertino JR: Fluorouracil in colorectal cancer - A tale of two drugs: Implications for biochemical modulation. J Clin Oncol 15:368-381, 1997.
4. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992.
5. Piedbois P, Michiels S, for the Meta-Analysis Group in Cancer: Survival benefit of 5FU/LV over 5FU bolus in patients with advanced colorectal cancer: An updated meta-analysis based on 2,751 patients (abstract 1180). Proc Am Soc Clin Oncol 22:294, 2003.
6. de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bi-monthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15:808-815, 1997.
7. The Meta-Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308, 1998.
8. O'Dwyer PJ, Manola J, Valone FH, et al: Fluorouracil modulation in colorectal cancer: lack of improvement with N-phosphonoacetyl-l-asparatic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule - An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol 19:2413-2421, 2001.
9. Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectivity in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281, 1998.
10. Schuller J, Cassidy J, Dumont E, et al: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291-297, 2000.
11. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-time treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282-2292, 2001.
12. Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 19:4097-4106, 2001.
13. Borner NM, Dietrich D, Popescu R, et al: A randomized phase II trial of capecitabine (CAP) and two different schedules of irinotecan (IRI) in first-line treatment of metastatic colorectal cancer (MCC) (abstract 1068). Proc Am Soc Clin Oncol 22:266, 2003.
14. Patt YZ, Lin E, Leibmann J, et al: Capecitabine plus irinotecan for chemotherapy-naïve patients with metastatic colorectal cancer (MCRQ: US multicenter phase II trial (abstract 1130). Proc Am Soc Clin Oncol 22:281, 2003.
15. Taguchi T, Wakui A, Hasegawa K, et al: Phase I clinical study of CPT-11. Research group of CPT-11 [in Japanese]. Gan To Kagaku Ryoho 17:115-20, 1990.
16. Rothenberg ML, Kuhn JG, Burris HA, 3rd, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204, 1993.
17. Rougier P, Bugar R, Douillard TY, et al: A phase II study of CPT-11 (irinotecan) in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with 5-FU based chemotherapy. J Clin Oncol 15:251-260, 1997.
18. Conti JA, Kemeny NE, Saltz LB, et al: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 114:709-715, 1996.
19. Cunningham D, Pyrhonen S, James RD, et al: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1998.
20. Rougier P, Van Cutsern E, Bajetta E, et al: Randomized trial of irino tecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412, 1998.
21. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905-914, 2000.
22. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomized trial. Lancet 35:1041-1047, 2000.
23. Saltz LB, Douillard JY, Pirotta N, et al: Irinotecan plus fluorouracil/ leucovorin for metastatic colorectal cancer: A new survival standard. Oncologist 6(1):81-91, 2001.
24. Sargent DJ, Niedzwiecki D, O'Connell MJ, et al: Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N Engl J Med 135:905-914, 2001.
25. Rothenberg ML, Meropol NJ, Poplin EA, et al: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 19: 3801-3807, 2001.
26. Kohne C-H, Van Cutsem E, Wils JA, et al: Irinotecan improves the activity of the AIO regiment in metastatic colorectal cancer: Results of EORTC GI Group study 40986 (abstract 1018). Proc Am Soc Clin Oncol 22:254, 2003.
27. Wilson RH, Lehky T, Thomas RR, et al: Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20:1767-1774, 2002.
28. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000.
29. Grothey A, Deschler B, Kroening H: Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC) (abstract 512). Proc Am Soc Clin Oncol 21:129a, 2002.
30. Andre T, Figer A, Cervantes A, FOLFOX 7 compared to FOLFOX 4. Preliminary results of the randomized optimox study (abstract 1016). Proc Am Sac Clin Oncol 22:253, 2003.
31. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004.
32. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR Study. J Clin Oncol 22:1-9, 2004.
33. Colucci G, Maiello E, Gebbia V, et al: Preliminary results of a randomized multicenter trial of the Gruppo Oncologico Italia Meridionale (GOIM) comparing FOLFIRI vs FOLFOX in advanced colorectal cancer patients (abstract 1021). Proc Am Soc Clin Oncol 22:255, 2003.
34. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of 5-fluorouracil/leucovorin, irinotecan, and oxaliplatin in the course of their treatment (in press). J Clin Oncol 22(7):1209-1214, 2004.
35. Fischel JL, Rostagno P, Formento P, et al: Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: Results on human colon cancer cell lines. Br J Cancer 84:579-585, 2001.
36. Mini E, Nobili S, Mazzocchi S, et al: Biweekly chemotherapy (CHT) with oxaliplatin (OHP), irinotecan (CPT-11), infusional 5-fluorouracil/folic acid in patients with metastatic colorectal cancer pretreated with CPT-11 or OHP based CHT (abstract 1503). Proc Am Soc Clin Oncol 22:374, 2003.
37. Souglakos J, Mavroudis D, Kakolyris S, et al: Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: A multicenter phase II trial. J Clin Oncol 20: 2651-2657, 2002.
38. Roth AD, Seium Y, Ruhstaller T, et al: Oxaliplatine (OXA) combined with irinotecan (CPT-11) and 5FU/leucovorin (OCFL) in metastatic colorectal cancer (MCRC): A phase I-II study (abstract 570). Proc Am Soc Clin Oncol 21:143a, 2002.
39. Reina J.J., Sanchez-Rovira P, Salvador J, et al: Biweekly administration of oxaliplatin (OX), irinotecan (CPT-11) and 5-fluorouracil as first line treatment of advanced or metastatic colorectal cancer (abstract 1284). Proc Am Soc Clin Oncol 22:320, 2003.
40. Jamison RL, Donohue JH, Nagorney DM, et al: Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 132:505-510, 1997.
41. Fong Y, Fortner J, Sun RL, et al: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 230:309-318, 1999.
42. Meta-Analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 88:252-258, 1996.
43. Bismuth H, Adam R, Levi F, et al: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509-522, 1996.
44. Alberts SR, Donohue JH, Mahoney MR, et al: Liver resection after 5-fluorouracil, leucovorin and oxaliplatin for patients with metastatic colorectal cancer (MCRC) limited to the liven A North Central Cancer Treatment Group (NCCTG) phase II study (abstract 1053). Proc Am Soc Clin Oncol 22:263, 2003.
45. Hurwitz H, Fehrenbacher L, Cartwright T, et al: Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal. cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC (abstract 3646). Proc Am Soc Clin Oncol 22, 2003.
46. Cunningham D, Humblet Y, Siena S, et al: Cetuximab (C225) alone or in combination with irinotecan in patients with epidermal growth factor receptor-positive, irinotecan-refractory metastatic colorectal cancer (abstract 1012). Proc Am Soc Clin Oncol 22:252, 2003.
47. Sun Y, Guan ZZ, Jin ML, et al: A multicenter randomized phase II trial of oxaliplatin alone and in combination in patients with advanced colorectal cancer in China (abstract 979). Proc Am Soc Clin Oncol 18:255a, 1999.
48. Diaz-Rubio E, Marty M, Extra JM, et al: Multicenter phase II study with oxaliplatin (L-OHP) in 5-FU refractory patients with advanced colorectal cancer (ACC) (abstract 514). Proc Am Soc Clin Oncol 14, 1995.